Key result
Drug-coated balloons deliver local antiproliferative therapy to prevent restenosis without permanent implants.
Answers are grounded in this paper and cite their sources.
Over the last few years, drug-coated balloon (DCB) therapy has emerged as a promising therapeutic intervention for the management of obstructive cardiovascular disease. The dictum of this novel technology is that effective prevention of restenosis can be achieved by the short-term transfer of antiproliferative drug to local arterial tissue by means of a single prolonged balloon angioplasty dilatation. Its main attraction is that no foreign body is implanted eliminating thus the risk of late inflammatory response to device components without preventing positive remodeling. Here, we discuss the evidence regarding the effectiveness of DCB in different lesion types and clinical settings as well as the types of DCB commercially available or under development.
No takes yet. Share an insight, caveat, or question.
Giannini et al. (2013) conducted a review in Obstructive cardiovascular disease. Drug-coated balloon (DCB) therapy was evaluated on Prevention of restenosis. Drug-coated balloon therapy transfers antiproliferative drugs locally via balloon angioplasty to prevent restenosis in obstructive cardiovascular disease without implanting a foreign body.
Synapse has enriched 10 related papers. Consider them for comparative context: